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Abstract 24 
UVB irradiation induces harmful photochemical reactions, including formation of 25 
cyclobutane pyrimidine dimers (CPDs) in DNA. Accumulation of unrepaired CPD lesions 26 
causes inflammation, premature ageing and skin cancer. Photolyases are DNA repair enzymes 27 
that can rapidly restore DNA integrity in a light-dependent process called photoreactivation, 28 
but these enzymes are absent in humans. Here, we present a novel mRNA-based gene therapy 29 
method that directs synthesis of a marsupial, Potorous tridactylus, CPD-photolyase in 30 
cultured human keratinocytes. Pseudouridine was incorporated during in vitro transcription to 31 
make the mRNA non-immunogenic and highly translatable. Keratinocytes transfected with 32 
lipofectamine-complexed mRNA expressed photolyase in the nuclei for at least 2 days. 33 
Exposing photolyase mRNA-transfected cells to UVB irradiation resulted in significantly less 34 
CPD in those cells that were also treated with photoreactivating light, which is required for 35 
photolyase activity. The functional photolyase also diminished other UVB-mediated effects, 36 
including induction of IL-6 and inhibition of cell proliferation. These results demonstrate that 37 
pseudouridine-containing photolyase mRNA is a powerful tool to repair UVB-induced DNA 38 
lesions. The pseudouridine-modified mRNA approach has a strong potential to discern 39 
cellular effects of CPD in UV-related cell biological studies. The mRNA-based transient 40 
expression of proteins offers a number of opportunities for future application in medicine. 41 
Key words: pseudouridine-modified mRNA – mRNA therapy – photolyase – human 42 
keratinocyte – UVB – cyclobutane pyrimidine dimers 43 
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1. Introduction 44 
Ultraviolet (UV) radiation, especially UVB (290-320 nm), is a common environmental 45 
carcinogen that induces harmful photochemical reactions in the skin [1]. UVB photons 46 
absorbed by the DNA cause a variety of photoproducts, including cyclobutane pyrimidine 47 
dimers (CPD), which is the most frequent and deleterious photolesion. It forms in double-48 
stranded DNA when two adjacent pyrimidine bases in one strand fuse together [2]. 49 
Accumulated CPDs induce apoptosis, inflammation, immune suppression, and mutations that 50 
may lead to melanoma and other types of skin cancer [3-6]. Timely repair of damaged DNA 51 
is critical to prevent these adverse effects. In humans and rodents, photoproducts are removed 52 
by nucleotide excision repair (NER), a versatile repair system for removal of bulky DNA 53 
lesions. Genetic defects in NER result in photosensitive disorders, such as xeroderma 54 
pigmentosum and Cockayne’s syndrome, in which patients have UV sensitivity and display 55 
skin cancer proneness and/or accelerated aging [7, 8]. NER excises CPDs at a very low rate, 56 
requiring hours to days to restore DNA integrity [9-12]. Interestingly, in most organisms from 57 
bacteria to marsupials, CPDs are rapidly removed by photolyases that specifically recognize 58 
and split these dimers into monomers using energy from visible light [13-15]. Due to an 59 
evolutionary loss, photolyases are absent in placental mammals, including humans, which 60 
therefore solely rely on NER for removal of photolesions [16-19]. 61 
Studies have demonstrated that CPD photolyases from phylogenetically diverse organisms, 62 
such as cyanobacteria (Anacystis nidulans) [20], yeast [21] or marsupials [22], can function in 63 
mammalian cells. Liposome-encapsulated CPD photolyase enzyme from Anacystis nidulans 64 
has been shown to protect cultured mammalian cells and human skin from the effects of UVB 65 
[20, 23-26]. Superior resistance to UVB-induced sunburn, immune suppression and 66 
carcinogenesis were demonstrated for transgenic mice ubiquitously expressing CPD 67 
photolyase of the rat kangaroo (Potorous tridactylus) [22, 27-29]. Mammalian cell lines 68 
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stably expressing marsupial CPD photolyases also demonstrated reduced apoptosis and 69 
mutation frequencies when exposed to UVB radiation [30-33]. To study sunlight-induced 70 
DNA damage and their repair in primary cells, transient adenovirus-mediated CPD photolyase 71 
expression was used [34, 35]. 72 
Gene therapy for the replacement of defective genes or for the expression of therapeutic 73 
proteins has made great progress in the last decade. After exploring numerous systems for 74 
expressing the encoded proteins [36], in vitro transcribed mRNA seems to be the most 75 
suitable tool for transient protein expression [37]. It has many features that make mRNA-76 
mediated gene transfer especially valuable for functional characterization of encoded protein. 77 
The transfected mRNA is translated with high efficiency in any cell, including primary and 78 
non-dividing mammalian cells [37]. Importantly, when mRNA is delivered to the cell, only 79 
the encoded protein of interest is generated, unlike other vectors, such as plasmids that 80 
contain sequences for additional proteins, or viral vectors that not only code for but also carry 81 
viral proteins into the cell. In the last several years, mRNA-mediated transfection technology 82 
has improved tremendously [38]. It is now well documented that incorporation of 83 
pseudouridine (Ψ), a naturally-occurring modified nucleoside, into mRNA makes it less 84 
immunogenic by avoiding the activation of RNA sensors [39-41]. In vitro-transcribed mRNA 85 
containing pseudouridine (Ψ-mRNA) is also translated more efficiently than mRNA 86 
containing unmodified nucleosides [42]. We have demonstrated that the presence of Ψ 87 
nucleosides improved the stability of RNA [43] and diminished both activation of RNA-88 
dependent protein kinase (PKR) and inhibition of translation [44]. A newly established 89 
preparative HPLC purification procedure was critical to obtain Ψ-mRNA that is free of 90 
aberrant transcription products, resulting in superior translational potential and no 91 
immunogenicity [45, 46]. 92 
Here, we present a novel mRNA-based gene therapy method that directs functional 93 
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photolyase synthesis in human keratinocytes. Our study demonstrates that delivery of HPLC-94 
purified, Ψ-mRNA encoding CPD-photolyase into keratinocytes leads to the rapid repair of 95 
UVB-induced CPDs and suggest that such mRNA has therapeutic potential to repair damage 96 
caused by exposure to the sun and other sources of UV radiation. 97 
2. Material and methods 98 
2.1 RNA synthesis 99 
A codon-optimized photolyase gene from Potorous tridactylus (rat kangaroo) containing GC-100 
rich codons for superior translation was synthesized by Entelechon (Bad Abbach, Germany). 101 
The optimization increased the GC-content of the photolyase coding sequence (Accession: 102 
D26020) from 51.8% to 65.0%. Messenger RNAs encoding CPD-photolyase (CPD-PL Ψ-103 
mRNA) and enhanced green fluorescent protein (eGFP Ψ-mRNA) were transcribed as 104 
previously described [42] from linearized plasmids (pTEV-CPD-PL-A101 and pTEVeGFP-105 
A101), using the Megascript T7 RNA polymerase kit (Ambion, Austin, TX) in which UTP 106 
was replaced with pseudouridine triphosphate (TriLink, San Diego, CA). Subsequently, the 107 
mRNA was HPLC purified as described [45], and provided with a 5’ cap using capping 108 
enzyme and 2’-O-methyltransferase according to the manufacturer (CellScript, Madison, WI). 109 
The RNA was transcribed to contain an encoded 101-nt long 3’ poly(A) tail, which was 110 
extended with ~ 300 nucleotides using poly(A) polymerase (USB, Cleveland OH). RNA 111 
samples were analyzed by agarose gel electrophoresis for quality assurance. The mRNAs 112 
were shown to be free of dsRNA contaminants using dsRNA-specific J2 mAb (English & 113 
Scientific Consulting, Budapest, Hungary) in a dot-blot assay [45]. The mRNAs were stored 114 
in siliconized tubes at -20°C. 115 
2.2 Cell cultures 116 
The human keratinocyte cell line HaCaT was obtained from the ATCC and grown in high 117 
glucose DMEM (PAA, Traun, Austria) supplemented with 2 mM L-glutamine (PAA), 10% 118 
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heat-inactivated fetal bovine serum (Lonza, Verviers, Belgium) and 0.5% 119 
antibiotic/antimycotic solution (Sigma-Aldrich, St. Louis, MO, USA) at 37°C in a 5% CO2 120 
atmosphere. Normal human epidermal keratinocytes (NHEK) were isolated from healthy 121 
adult skin derived from plastic surgery and cultured in EpiLife serum-free, complete 122 
keratinocyte growth medium (Life Technologies, Carlsblad, CA, USA). Ethics approval was 123 
received from the National Scientific and Research Ethics Commission. HaCaT cells and 124 
second passage NHEK were used at 70-80% confluency in each experiment. 125 
2.3 Transient transfection and treatments 126 
HaCaT cells and NHEK were seeded into 96-well plates at a density of 2 × 104 cells per well 127 
one day prior to transfection. Aliquots of RNA samples (0.25 µg) were complexed with 0.8 µl 128 
Lipofectamine LTX-PLUS (Life Technologies) in a final volume of 100 µl of EpiLife and the 129 
complexed RNA was added to each well. After one hour the lipofectamine-RNA complex 130 
was replaced with 100 µl culture medium. At 20 h post transfection, cells covered with 50 µl 131 
Dulbecco’s Phosphate Buffer Saline (DPBS) (Life Technologies) were subjected to 20 132 
mJ/cm
2
 UVB using two TL-20W/12 bulbs (Philips). Immediately after UVB treatment, cells 133 
were either exposed to visible light using a F18W Daylight fluorescent bulb (Sylvania,) at a 134 
distance of 16 cm and using a 4 mm thick glass filter as a shield or kept in the dark for one 135 
hour. Cells were further cultured in complete medium for the indicated times. Cell viability 136 
was determined by the EZ4U assay (Biomedica Gruppe, Vienna, Austria), according to the 137 
manufacturer. 138 
2.4 Western blot analysis 139 
Cells were lysed in RIPA buffer (R0278, Sigma-Aldrich) containing protease inhibitor 140 
cocktail (Sigma-Aldrich). Proteins were separated on 10% polyacrylamide gels and 141 
transferred to nitrocellulose membranes. The membrane was blocked in 5% non-fat dry milk 142 
for 1 h and incubated overnight at 4C with primary CPD-photolyase antibody [27] diluted 143 
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(1:500) in PBGTNa made of PBS containing 0.5% bovine serum albumin (BSA, Amresco, 144 
Solon, OH, USA), 0.05% gelatin (Sigma-Aldrich), 0.05% Tween-20 (Amresco) and 300 mM 145 
NaCl (VWR, San Diego, CA, USA). HRP-conjugated anti-rabbit IgG was used as a 146 
secondary antibody (1:3000; 1 h, at room temperature, BioRad, Berkeley, CA, USA). Proteins 147 
were visualized with the Pierce ECL Plus Western blotting detection system (Thermo Fisher 148 
Scientific, Rockford, IL, USA). 149 
2.5 Fluorescence microscopy 150 
Expression of eGFP in HaCaT cells was documented using an epifluorescent Zeiss Axiovert 151 
100 microscope mounted with a Zeiss AxioCam MRc 5 digital camera using AxioVision 4.8 152 
and 0.4-second exposure time. 153 
In the expression studies, cells were fixed with 4% paraformaldehyde (Sigma-Aldrich) and 154 
permeabilized with 1% Triton X-100 (Amresco). Before immunolabeling, cells were blocked 155 
in 20% FBS and then probed overnight at 4C with CPD-photolyase-specific antibody diluted 156 
(1:100) in PBGTNa. FITC-conjugated secondary antibody (1:2000; anti-rabbit IgG; 157 
Vectashield, Irvine, CA, USA) was added for 2 h at room temperature. 158 
For the analysis of CPDs, experiments were carried out as described above, except, before 159 
blocking, cellular DNA was denatured in 2 M HCl (VWR) at room temperature for 30 min 160 
and then probed with primary anti-CPD antibody (TDM-2, Cosmo Bio, Tokyo, Japan) diluted 161 
(1:1500) in PBS containing 5% FBS for 30 min. Alexa Fluor 568-conjugated anti-mouse IgG 162 
was used as secondary antibody (1:2000; Life Technologies). In both studies, nuclei were 163 
stained with DAPI (Vectashield) and cells were analyzed by fluorescence microscopy. 164 
2.6 Enzyme-linked immunosorbent assay (ELISA) 165 
Genomic DNA was extracted by the QIAamp DNA mini kit (Qiagen, Hilden, Germany), 166 
according to the manufacturer. Flat-bottom 96-well plate were precoated with 0.003% 167 
protamine sulfate (50 µl/well, Sigma-Aldrich) and incubated overnight with denatured DNA 168 
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(15 ng/well) at 37°C. The plates were washed with PBS containing 0.05% Tween-20 and 169 
incubated with 2% FBS at 37°C for 30 min to prevent non-specific binding of the antibody 170 
and washed again. Anti-CPD monoclonal antibody (TDM2) diluted in PBS (1:1000) was used 171 
as primary antibody at 37°C for 30 min. The plates were washed and then incubated with 172 
HRP conjugated anti-mouse IgG secondary antibody (1:3000, BioRad) at 37°C for 30 min. 173 
After washing, samples were equilibrated with citrate-phosphate buffer (pH 5.0; 150 µl/well), 174 
then substrate solution was added to each well (100 µl/well) containing 0.04% o-175 
phenylenediamine (Sigma-Aldrich) and 0.0063% H2O2 in citrate-phosphate buffer. Samples 176 
were incubated at 37°C for 15 min, and 2 M sulfuric acid (VWR) was added (50 µl/well) to 177 
stop the reaction and absorbance was measured at 492 nm using an Anthos 2020 microplate 178 
reader (Biochrom Ltd; Cambridge; UK). 179 
The concentration of IL-6 in the supernatants was determined by the human IL-6 Quantikine 180 
ELISA kit (R&D Systems, Minneapolis, MN, USA), according to the manufacturer. 181 
2.7 RNA extraction and quantitative RT-PCR 182 
Total RNA was isolated using TRI reagent (MRC, Cincinnati, OH, USA) followed by DNase 183 
I treatment (Fermentas, St. Leon-Rot, Germany). To quantitate IL-6, SDHA, and PGK1 184 
mRNAs, reverse transcription was performed using the High-Capacity cDNA Reverse 185 
Transcription Kit (Life Technologies), according to the manufacturer. Quantitative PCR was 186 
performed on the ABI 7900 HT Sequence Detection System (Life Technologies) using a 187 
reaction mixture containing 1x PCR buffer, 3 mM MgCl2 and 0.1 mM dNTP mix 188 
(Fermentas), 1x TaqMan Gene Expression assay (Life Technologies), 1x ROX reference dye 189 
(Life Technologies), 0.0125 U Taq DNA polymerase (Fermentas) and 12.5 ng cDNA 190 
template in a total volume of 10 μl. qPCR was performed in 384-well optical plates (Life 191 
Technologies) and the PCR program used for amplification was: 94°C 1 min, followed by 40 192 
cycles of 94°C for 12 sec and 60°C for 45 sec. The following TaqMan Gene Expression 193 
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assays were used: IL-6 (Hs00985639_m1), SDHA (Hs00188166_m1) and PGK1 194 
(Hs00943178_g1), the sequences are proprietary and not released by the company. SDHA and 195 
PGK1 mRNA levels were used for normalization [47]. 196 
2.8 Statistical analysis 197 
All statistical analyses were performed using GraphPad Prism version 5.0 (GraphPad 198 
Software Inc., San Diego, CA, USA). Values were compared between photoreactivated and 199 
non-photoreactivated samples using two-tailed, paired t-test. A p value of less than 0.05 was 200 
considered as statistically significant. 201 
3. Results 202 
3.1 Synthesis of CPD-specific photolyase in human keratinocytes transfected with the 203 
encoding pseudouridine-modified mRNA 204 
To test whether pseudouridine-modified mRNA (Ψ-mRNA) is translated in human 205 
keratinocytes, eGFP-encoding Ψ-mRNA was complexed with lipofectamine LTX and 206 
delivered to the cells. The expression of eGFP was monitored by fluorescence microscopy at 207 
different time points after transfection. eGFP was detectable as early as 1 h, peaked between 6 208 
and 20 h, and its level gradually declined, but remained detectable even at 48 h after mRNA 209 
transfection (Fig. 1a). This eGFP mRNA served as a control for photolyase experiments. 210 
Using western blotting, high levels of CPD-photolyase synthesized from the transfected CPD-211 
PL Ψ-mRNA could be detected in both HaCaT cells and normal human epidermal 212 
keratinocytes (NHEK) at 20 h post transfection (Fig. 1b and c). The photolyase migrated with 213 
the expected size of 62 kDa (Fig. 1c) and localized in the nuclei of keratinocytes, as 214 
demonstrated by immunofluorescence imaging (Fig. 1d). 215 
3.2 Enhanced repair of UVB-induced CPDs in keratinocytes is mediated by CPD-216 
photolyase translated from the encoding Ψ-mRNA 217 
10 
 
To investigate whether CPD-photolyase translated from the encoding Ψ-mRNA is functional 218 
and capable of cleaving CPDs, HaCaT cells were first transfected with lipofectamine-219 
complexed CPD-PL Ψ-mRNA. Twenty hours later, the transfected cells were exposed to 20 220 
mJ/cm
2
 UVB. Immediately thereafter, cells were either exposed to photoreactivating light, or 221 
left in the dark for 1 hour. Using CPD-specific antibodies, efficient repair of these 222 
photolesions could be detected in CPD-PL Ψ-mRNA-transfected cells that were subjected to 223 
photoreactivating light, while those deprived from this energy source or transfected with 224 
eGFP Ψ-mRNA contained high levels of CPDs, when it was analyzed immediately after the 225 
photoreactivation or incubation in the dark (Fig. 2). 226 
To quantitate the amount of CPDs removed from the genomic DNA of the CPD-PL Ψ-227 
mRNA-transfected keratinocytes immediately after exposure to visible light, a CPD-specific 228 
ELISA was used. We determined that photoreactivation of UVB-irradiated, CPD-PL Ψ-229 
mRNA-transfected cells eliminated more than 60% of the CPDs, as compared to cells kept in 230 
the dark or transfected with control eGFP Ψ-mRNA (Fig. 3, left panel). 231 
UVB treatment of keratinocytes results in the induction of apoptosis and reduction in cell 232 
proliferation. Cell viability, determined 24 h after UVB irradiation, demonstrated that 233 
photoreactivation significantly increased cell survival of CPD-PL Ψ-mRNA transfected 234 
keratinocytes compared to those that were kept in the dark or transfected with eGFP Ψ-235 
mRNA (Fig. 3, right panel). 236 
3.3 Photorepair of CPDs in keratinocytes transfected with CPD-photolyase Ψ-mRNA 237 
reduces UVB-induced IL-6 expression 238 
To determine whether repair of CPDs in photolyase mRNA-transfected cells can ameliorate 239 
UVB-triggered cytokine induction, we measured the expression of IL-6 mRNA and protein 240 
using qRT-PCR and ELISA. We found that the repair of CPDs in CPD-PL Ψ-mRNA 241 
transfected keratinocytes significantly decreased the levels of IL-6 mRNA measured 24 h 242 
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after UVB irradiation (Fig. 4). Accordingly, the levels of IL-6 protein in the supernatants of 243 
photolyase mRNA-transfected keratinocytes were also significantly reduced at 6 and 24 h 244 
(Fig. 4). 245 
4. Discussion 246 
Intracellular delivery of therapeutic proteins has been performed using many different viral 247 
and non-viral techniques. Recent advancements in the use of mRNA for expressing the 248 
encoded proteins in mammalian cells made the present study possible. Here, we demonstrate 249 
that HPLC-purified, lipofectamine-complexed mRNAs containing pseudouridine are 250 
efficiently taken up and translated by primary human keratinocytes and an established 251 
keratinocyte cell line, with greater than 95% of the cells expressing the protein encoded by the 252 
mRNA (eGFP or photolyase). The CPD-photolyase of Potorous tridactylus encoded by the 253 
mRNA is efficiently translated into a functional protein that correctly localized to the nucleus. 254 
The CPD-photolyase mediated rapid repair of UVB-induced cyclobutane pyrimidine dimers. 255 
This led to a significant survival advantage and reduction in IL-6 mRNA and protein 256 
secretion. 257 
This is the first report of transient expression of functional CPD-photolyase in human 258 
cells from transfected mRNA. Several studies have reported successful protection from UVB-259 
induced damage using topical application of liposomes-encapsulating recombinant CPD-260 
photolyase protein, however, direct evidence for nuclear localization of this cyanobacteria-261 
derived protein has not been provided [20, 23, 26, 48-51]. Here, we found that nucleoside-262 
modified mRNA encoding CPD-photolyase correctly located to the nucleus and removed 263 
more than 60% of CPDs within the first hour of photoreactivation. In placental mammals that 264 
lack a functional CPD-photolyase, DNA repair of CPDs is performed by the NER complex 265 
that in mammals contains 9 major proteins and over 20 associated genes. In UVB-irradiated 266 
primary keratinocytes, NER-mediated repair removed only 30% of the CPDs in 24 hours [52]. 267 
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If a cell containing CPD lesions divides before the repair can be completed, an alteration to 268 
the DNA, i.e. mutation, can occur in the daughter cell and all of its progeny [6]. Such 269 
mutations are the initial steps in the development of sun-induced skin cancers. As shown for 270 
Potorous tridactylus CPD photolyase-expressing transgenic mice [27-29], very rapid 271 
clearance of CPDs by photolyase produced from the transfected mRNA should result in a 272 
large reduction of DNA mutations and other CPD-driven deleterious effects of UVB. 273 
It is well established that UVB irradiation induces cell cycle arrest and inhibits cell 274 
proliferation, which is partly mediated by CPD photolesions [53, 54]. Removal of CPDs after 275 
photoreactivation of keratinocytes transfected with photolyase mRNA increased survival, 276 
confirming that CPDs are major contributors to cell death after UVB irradiation [22, 31, 55, 277 
56] and demonstrating that CPD-photolyase mRNA transfection is an effective tool for 278 
photorepair. 279 
UVB irradiation also induces erythema in the skin [57] and the involvement of the 280 
proinflammatory cytokine IL-6 has been considered [58, 59]. Consistent with these 281 
observations, we demonstrate that enhanced repair of CPDs in photolyase mRNA-transfected 282 
keratinocytes reduced UVB-induced IL-6 expression when cells were subjected to 283 
photoreactivation compared to those kept in dark. CPD-photolyase mediated repair of UVB-284 
induced damage did not return IL-6 levels to non-irradiated levels likely due to the presence 285 
of modified host RNA acting through TLR3 [60] and other UVB mediated effects, including 286 
the induction of reactive oxygen species, protein–DNA crosslinking, oxidative base damage 287 
(e.g. 8-oxo-7,8-dihydroxyguanine), single-strand breaks and a 6-4 photoproduct (6-4PP). 288 
Thus, these results demonstrate that CPDs play an important but not exclusive role in 289 
triggering IL-6 release from keratinocytes, and transfection of Ψ-mRNA encoding CPD-290 
photolyase reduces production of IL-6 by UVB irradiated keratinocytes and supports their 291 
survival. 292 
13 
 
In summary, we demonstrate that in vitro-synthesized, pseudouridine-containing mRNA 293 
encoding Potourus photolyase is a powerful tool to rapidly repair UVB-induced CPD lesions 294 
in human keratinocytes. This novel mRNA-based gene therapy method efficiently directs 295 
functional protein synthesis providing number of opportunities for future dermatological 296 
applications if the nucleic acid delivery to intact epidermis has been resolved. Concerning 297 
photolyase, thus it could be used in UV-sensitive diseases [7, 8] and in the prevention of skin 298 
cancer and tanning, which requires CPD formation to increase the production of melanin [61]. 299 
Ψ-mRNA encoding CPD-photolyase is also a new model system that uses primary human 300 
keratinocytes to investigate the cellular and molecular effects of UVB irradiation with the 301 
ability to distinguish between CPD-dependent and CPD-independent events and the potential 302 
to deliver and study any protein of interest. 303 
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Figure captions 483 
Fig. 1. Translation of CPD-photolyase-encoding, Ψ-modified mRNA in keratinocytes. 484 
HaCaT cells or normal human epidermal keratinocytes (NHEK) were transfected with 485 
lipofectamine-complexed Ψ-mRNA encoding eGFP or CPD-photolyase. Translated eGFP 486 
was detected at the indicated times post transfection in HaCaT cells transfected with eGFP Ψ-487 
mRNA by fluorescence microscopy (panel a) (original magnification ×20). Cells were lysed 488 
19 
 
at the indicated times (panel b) or at 20 h post transfection (panel c) and analyzed by western 489 
blot. Arrows mark positions of the 62 kDa CPD-photolyase and the loading reference, β-actin. 490 
CPD-photolyase protein was observed in NHEK transfected with CPD-PL Ψ-mRNA using 491 
immunofluorescent detection (panel d). Nuclei were visualized by DAPI staining (original 492 
magnification ×40). 493 
Fig. 2. Photorepair of CPDs in HaCaT cells transfected with CPD-PL Ψ-mRNA. HaCaT 494 
cells were transfected with lipofectamine-complexed Ψ-mRNA encoding CPD-photolyase or 495 
eGFP, or left untransfected (none). Twenty hours later, cells were subjected to 20 mJ/cm
2
 496 
UVB and immediately exposed to photoreactivating light or left in the dark for 1 h. 497 
Immediately after photoreactivation or incubation in the dark, CPDs were detected by 498 
immunofluorescent labeling with CPD-specific antibody and Alexa-conjugated secondary 499 
antibody (red). Nuclei were visualized by DAPI staining. Images are representatives of three 500 
independently performed experiments (original magnification ×20). 501 
Fig. 3. Reduced levels of CPDs and improved cell viability in photolyase mRNA-502 
transfected keratinocytes exposed to UVB and photoreactivating light. HaCaT cells and 503 
NHEK were irradiated with a physiological dose of UVB (20 mJ/cm
2
) 20 h after delivery of 504 
Ψ-mRNAs and immediately exposed to photoreactivating light (+Phr) or left in the dark (-505 
Phr) for 1 h. After photoreactivation or incubation in the dark, the amount of CPDs in the 506 
DNA of keratinocytes transfected with Ψ-mRNA encoding CPD-PL or eGFP was determined 507 
by ELISA (left panel). The OD values obtained were in the linear range of the ELISA. Cell 508 
viability was determined by EZ4U assay at 24 h after UVB irradiation (right panel). The 509 
values were calculated relative to those obtained with cells that were not UVB irradiated. 510 
Significance was assessed by paired t-test, asterisk, p<0.05. Error bars represent the standard 511 
error of the mean. The results are means of three independent experiments. 512 
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Fig. 4. Photorepair of CPDs reduces UVB-induced IL-6 expression in HaCaT cells. Cells 513 
were transfected with lipofectamine-complexed CPD-PL Ψ-mRNA, 20 h later irradiated with 514 
20 mJ/cm
2
 UVB and then immediately exposed to photoreactivating light (+Phr) or left in the 515 
dark (-Phr) for 1 h. Total RNA was isolated and supernatants were collected 6 and 24 h after 516 
UVB irradiation. Levels of IL-6 mRNA were determined by qRT-PCR. Values measured in 517 
UVB irradiated –Phr or +Phr cells were normalized to those measured in the Ψ-mRNA-518 
transfected, non-UVB irradiated control cells. IL-6 was quantitated in the supernatant by 519 
ELISA. Asterisks indicate significant differences (paired t-test; p<0.05) between 520 
photoreactivated (+Phr) and non-photoreactivated (-Phr) samples. Error bars represent the 521 
standard error of the mean. Three independent experiments were performed, each in triplicate. 522 
